Indivior Shareholders Approve Merger With Supernus
Indivior shareholders approved the proposed merger with Supernus on October 15, 2026, with 94% of votes cast in favor. The transaction, announced in August 2026, is expected to close on November 2, 2026. The combined company will operate as Supernus, Inc., trading on Nasdaq under the ticker SUPN. The combination will create a diversified biopharmaceutical company focused on central nervous system diseases. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Indivior Pharmaceuticals Inc. published the original content used to generate this news brief on October 16, 2026, and is solely responsible for the information contained therein. (C)
Indivior shareholders approved the proposed merger with Supernus on October 15, 2026, with 94% of votes cast in favor. The transaction, announced in August 2026, is expected to close on November 2, 2026. The combined company will operate as Supernus, Inc., trading on Nasdaq under the ticker SUPN. The combination will create a diversified biopharmaceutical company focused on central nervous system diseases.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Indivior Pharmaceuticals Inc. published the original content used to generate this news brief on October 16, 2026, and is solely responsible for the information contained therein.
(C)